September 12 – September 13
As Clinical Longevity Gains Momentum in China, 7th TimePie Longevity Forum Spotlights Evidence-Based Medicine
A speaker presents at the 6th TimePie Longevity Forum.
-Image courtesy of TimePie.
The 6th TimePie Longevity Forum took place on September 20–21, 2025
at the Greenland International Convention Center in Shanghai, China.
As longevity moves from laboratory promise toward clinical validation, China is emerging as one of the largest demand bases shaping the field’s next phase. On September 12–13, 2026, the 7th TimePie Longevity Forum will convene nearly 2,000 researchers, physicians, healthcare operators, technology companies and investors in Shanghai to examine how aging science can be translated into evidence-based, real-world medicine…
Registration
Registration is now open for the 7th TimePie Longevity Forum, taking place in Shanghai on September 12–13, 2026.
For professionals and organizations engaged in China’s fast-growing longevity market, global aging research, clinical translation, and the future of evidence-based longevity medicine, the Forum offers a timely opportunity to connect with the field’s key thinkers and decision-makers.
Reserve your spot at timepielongevityforum.com and use code LONGEVITY for 20% off at checkout.
Join the Forum to be part of the conversation defining how longevity science moves responsibly into real-world care.
Why China Matters
China’s aging population is accelerating demand for preventive and longevity-focused healthcare. Hospitals, private providers, and international innovators are expanding longevity services, creating a rapidly growing market. The TimePie Longevity Forum aims to connect science, clinical practice, and investment to support the sector’s development.
By the end of 2025, China’s population aged 60 and above had reached 323.38 million, accounting for 23% of the national population. This demographic shift is changing not only healthcare demand, but also how the country defines value in health.
Nearly a decade after the launch of Healthy China 2030, a national strategy for improving population health, China’s health agenda has placed growing emphasis on chronic disease management, lifecycle intervention and prevention-oriented care…
This momentum is already visible across China’s healthcare system. Leading public hospitals, including Xiangya Hospital, Zhongshan Hospital and the PLA General Hospital, have launched longevity or geriatric medicine clinics, while private groups such as SinoUnited Health and Huihai International Medical Center are shaping a premium market that moves beyond cosmetic anti-aging and supplements toward diagnostics, personalized intervention and continuous biomarker tracking.At the same time, China is becoming more accessible to advanced global longevity innovation. Places such as the Hainan Boao Lecheng Pilot Zone allow selected overseas-approved drugs, devices and
medical technologies to reach clinical exploration through special access channels. International players are responding accordingly, with US geroscience biotech companies, Swiss longevity clinics, and global health innovation groups entering China through flagship centers, joint ventures, and local partnerships.
At this point, the sector needs a platform that can connect science, clinical practice and capital. The 7th TimePie Longevity Forum is built for that role, bringing the field’s key players together to move longevity medicine toward more responsible clinical growth.
What the Forum Will Discuss
The 2026 Forum will explore how advances in aging science are being translated into clinical care and business opportunities. Experts will discuss scientific breakthroughs, commercialization strategies, emerging technologies, and evolving longevity practices. An international exhibition will showcase leading innovations across the field.
Positioned as one of Asia’s leading longevity forums, the 2026 event will bring together 40–50 international speakers to examine how aging science is moving from biology and clinical validation into clinic operations, investment and cross-border partnerships…
At the heart of the Forum is rigorous aging science. Leading researchers, including Raul Mostoslavsky and Barry Halliwell, will examine the fundamental shifts redefining aging biology, from stem cell regeneration and tissue homeostasis to epigenetic regulation and metabolic dysfunction.
By grounding the program in evidence, this segment helps attendees understand the scientific momentum shaping the next stage of longevity medicine, while separating credible advances from ideas that remain too early for clinical adoption. From this scientific foundation, the Forum will turn to market realization, using company and clinic case studies from China and global markets to examine how longevity innovation becomes scalable care.
Discussions will cover the commercialization of new diagnostics and intervention technologies, the pricing and retention of prevention-focused services, and special-access pathways for overseas-approved technologies.
The program will also include perspectives from longevity’s more experimental frontiers. Global pioneers including Aubrey de Grey and Dave Pascoe will bring perspectives from longevity theory, quantified-self practice and real-world longevity communities, showing how behaviors emerging outside formal healthcare can signal what medical systems may later need to address.
The global exhibition area will make the Forum’s scientific and market themes tangible. With around 30 international pioneers under one roof, it will showcase emerging products, service models and
technologies across regenerative medicine, advanced diagnostics and clinical longevity, turning longevity science into something attendees can see, compare and experience
Inside the 2026 Longevity Clinic White Paper
The 2026 White Paper will examine how longevity technologies can be responsibly adopted through clinical and regulatory pathways. It will provide guidance on clinic operations, industry standards, and the longevity healthcare ecosystem. The report is designed to help providers, investors, and technology companies navigate the market.
Each year, TimePie develops an industry white paper with academic and industry partners, including institutions such as Fudan University, to bring greater clarity to how longevity science, services and business models are evolving.As more aging-intervention technologies seek clinical pathways, longevity clinics are becoming a crucial interface between science, regulation and patient demand. The upgraded 2026 white paper will examine how these technologies can be responsibly adopted in China and global markets through approved or specially regulated pathways, while serving as a practical industry guide for defining the scope, standards and responsible operation of longevity clinics in China.
The report will examine the ecosystem behind longevity clinics, linking core biological materials, digital assessment platforms and physical clinic settings into a clearer view of how the value chain works in practice. By tracing these connections, the white paper will give medical aesthetics providers, premium health-check centers and investors a stronger basis for evaluating market entry, operational upgrades and compliant service development.
TimePie invites clinics, medical institutions, technology companies, investors and practitioners worldwide to contribute insights, case studies and practical experience to the research process.
Supporting Early-Stage Longevity Research
The Forum supports early-stage longevity research through the TimePie Longevity Research Grant. Funded by Forum proceeds, the grant backs promising projects in areas such as healthy aging and drug discovery. This initiative helps ensure that industry growth remains grounded in scientific evidence.
Beyond convening the longevity field, the Forum also serves as a funding channel for early-stage scientific research.
Through the TimePie Longevity Research Grant, all net proceeds from the Forum are used to support early-stage longevity projects. Launched after the Forum first became profitable, the grant has already supported research in areas such as senescent cell clearance, ovarian health and AI-guided drug discovery. Now in its second year, the 2026 grant is open to researchers worldwide and will support 3–4 projects globally.
By converting sponsorships, ticket sales and partnerships into research funding, TimePie aims to create a closer link between industry growth and scientific progress. In a field where clinical and commercial adoption must be guided by evidence, the grant reinforces the Forum’s commitment to building longevity medicine on a stronger scientific foundation.